Key facts
- BrainDTech’s last known valuation is $20.8M (Jul 2020).
- It has raised $3.4M; the latest was Later Stage VC ($1.5M) in Mar 2025.
- Notable investors include Bio4Dreams, Bridge4Pharma, F3F, International Manufacturing Solutions, Neuro-Zone — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BrainDTech
- ·The full record, as it builds
Funding rounds
No funding rounds for BrainDTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BrainDTech
Developer of a neurodegenerative disease diagnostic system designed to provide early detection of brain diseases through liquid biopsy. The company's platform provides a patented method for diagnosis, prognosis, and treatment monitoring for neurodegenerative, neurological, and inflammatory diseases based on miRNA inside microglia microvesicles, enabling doctors to predict brain diseases prior to symptoms.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2016
- Employees
- 5
- Website
- braindtech.com/
- Ownership
- Privately Held (backing)
BrainDTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BrainDTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BrainDTech in its N-PORT filings yet. We sweep new filings monthly.